Literature DB >> 15781518

RGS proteins: new players in the field of opioid signaling and tolerance mechanisms.

Guo-xi Xie1, Pamela Pierce Palmer.   

Abstract

In this article we review recent advances in our understanding of the crucial role of the Regulator of G protein Signaling (RGS) proteins in opioid signaling mechanisms and opioid tolerance development. Opioids exert their physiologic effects via complex G protein-coupled receptor-signaling mechanisms, and RGS proteins are now known to tightly regulate the G protein signaling cycle. RGS proteins contain GTPase-accelerating protein activity within their characteristic RGS domain and various other receptor signaling-related properties of their other functional domains. There have been more than 20 RGS proteins reported in the literature, and multiple RGS proteins have been shown to negatively regulate G protein-mediated opioid signaling, facilitate opioid receptor desensitization and internalization, and affect the rate at which opioid tolerance develops. Using RGS proteins as targets for future drug therapy aimed at modulating opioid effectiveness in both acute and chronic pain settings may be an important advance in the treatment of pain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15781518     DOI: 10.1213/01.ANE.0000147711.51122.4B

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  9 in total

Review 1.  Molecular Pharmacology of δ-Opioid Receptors.

Authors:  Louis Gendron; Catherine M Cahill; Mark von Zastrow; Peter W Schiller; Graciela Pineyro
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

2.  Decreased mu-opioid receptor signalling and a reduction in calcium current density in sensory neurons from chronically morphine-treated mice.

Authors:  Emma E Johnson; Billy Chieng; Ian Napier; Mark Connor
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

3.  Regulator of G protein signaling proteins differentially modulate signaling of mu and delta opioid receptors.

Authors:  Zhihua Xie; Zhisong Li; Lei Guo; Caiying Ye; Juan Li; Xiaoli Yu; Huifen Yang; Yulin Wang; Chongguang Chen; Dechang Zhang; Lee-Yuan Liu-Chen
Journal:  Eur J Pharmacol       Date:  2007-03-19       Impact factor: 4.432

4.  Chronic cold exposure increases RGS7 expression and decreases alpha(2)-autoreceptor-mediated inhibition of noradrenergic locus coeruleus neurons.

Authors:  Hank P Jedema; Stephen J Gold; Guillermo Gonzalez-Burgos; Alan F Sved; Ben J Tobe; Theodore Wensel; Anthony A Grace
Journal:  Eur J Neurosci       Date:  2008-05       Impact factor: 3.386

5.  Differential modulation of mu- and delta-opioid receptor agonists by endogenous RGS4 protein in SH-SY5Y cells.

Authors:  Qin Wang; Lee-Yuan Liu-Chen; John R Traynor
Journal:  J Biol Chem       Date:  2009-05-05       Impact factor: 5.157

Review 6.  Molecular and cellular mechanisms of the age-dependency of opioid analgesia and tolerance.

Authors:  Jing Zhao; Xin Xin; Guo-xi Xie; Pamela Pierce Palmer; Yu-guang Huang
Journal:  Mol Pain       Date:  2012-05-21       Impact factor: 3.395

7.  The BioAssay network and its implications to future therapeutic discovery.

Authors:  Jintao Zhang; Gerald H Lushington; Jun Huan
Journal:  BMC Bioinformatics       Date:  2011-07-27       Impact factor: 3.169

Review 8.  CNS genes implicated in relapse.

Authors:  Kara L Kuntz-Melcavage; Willard M Freeman; Kent E Vrana
Journal:  Subst Abuse       Date:  2008-09-25

9.  Splicing factor transformer-2β (Tra2β) regulates the expression of regulator of G protein signaling 4 (RGS4) gene and is induced by morphine.

Authors:  Shu-Jing Li; Ya Li; Shi-chao Cui; Yao Qi; Jing-Jing Zhao; Xiao-Yan Liu; Ping Xu; Xian-Hua Chen
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.